HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Clinical Trial ID NCT01494662

PubWeight™ 19.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01494662

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol 2014 1.21
2 Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013 1.19
3 HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer 2014 1.14
4 Treatment of HER2-positive breast cancer. Breast 2013 1.09
5 Treatment of Brain Metastases. J Clin Oncol 2015 1.03
6 Emerging strategies for treating brain metastases from breast cancer. Cancer Cell 2015 1.00
7 Breast cancer brain metastases: the last frontier. Exp Hematol Oncol 2015 0.99
8 Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta 2014 0.96
9 Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2012 0.94
10 Targeted therapies in brain metastases. Curr Treat Options Neurol 2014 0.93
11 Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience 2013 0.89
12 Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res 2015 0.88
13 Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer (Auckl) 2014 0.87
14 Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 2015 0.86
15 Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol 2014 0.82
16 Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 2016 0.81
17 EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed) 2016 0.79
18 Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. Curr Breast Cancer Rep 2014 0.79
19 Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol 2015 0.79
20 Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecol Oncol 2015 0.75
21 Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. Ther Adv Med Oncol 2016 0.75
22 Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer 2019 0.75
Next 100